Discover the elements of professional resources
The information you need is just a click away. You’ll find a comprehensive collection
of resources for you and your practice, from dosing recommendations to patient education.
Pivotal Studies
-
Clinical Trials for Review
Wolfgang U. Knauf, MD, PhD. Phase III randomized study of bendamustine compared
with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
Continue >>
This article is based upon the pivotal study that formed the basis for approval of TREANDA. The conclusions reached in this article are consistent with the TREANDA Prescribing Information, however, the article contains information that differs from the TREANDA Prescribing Information. Please review this article in conjunction with the accompanying full Prescribing Information.
To view these files, you must have Adobe
® Reader
® installed on your computer. If
you do not have the program, get it for free
here.
To view these files, you must have Adobe
® Reader
® installed on your computer. If
you do not have the program, get it for free
here.
Indications
TREANDA is indicated for the treatment of patients with chronic lymphocytic leukemia
(CLL). Efficacy relative to first-line therapies other than chlorambucil has not
been established.
TREANDA is indicated for the treatment of patients with indolent B-cell non-Hodgkin’s
lymphoma (NHL) that has progressed during or within 6 months of treatment with rituximab
or a rituximab-containing regimen.
Important Safety Information
- Serious adverse reactions, including myelosuppression, infections, infusion reactions
and anaphylaxis, tumor lysis syndrome, skin reactions including SJS/TEN, other malignancies,
and extravasation, have been associated with TREANDA. Some reactions, such as myelosuppression,
infections, and SJS/TEN (when TREANDA was administered concomitantly with allopurinol
and other medications known to cause SJS/TEN), have been fatal. Patients should
be monitored closely for these reactions and treated promptly if any occur
- Adverse reactions may require interventions such as decreasing the dose of TREANDA,
or withholding or delaying treatment
- TREANDA is contraindicated in patients with a known hypersensitivity to bendamustine
or mannitol. Women should be advised to avoid becoming pregnant while using TREANDA
- The most common non-hematologic adverse reactions associated with TREANDA (frequency ≥15%) were pyrexia, nausea, and vomiting. The most common hematologic abnormalities associated with TREANDA (frequency ≥15%) were anemia, thrombocytopenia, neutropenia, lymphopenia, and leukopenia
TO REPORT SIDE EFFECTS: Contact us at 1-800-896-5855 or usmedinfo@cephalon.com
